Cathie Wood Acquires Nvidia, ACHR, and Cryptocurrency Stocks While Selling AMD and EXAS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2025
0mins
Should l Buy EXAS?
Source: TipRanks
ARK Invest's Notable Purchases: Cathie Wood's ARK Invest made significant portfolio adjustments, including buying 93,374 shares of Nvidia and 971,423 shares of Archer Aviation, alongside various crypto stocks and biotech companies.
Position Trimming: ARK continued to reduce its stake in Advanced Micro Devices (AMD) by selling 14,087 shares and offloaded 932,161 shares of Exact Sciences following its acquisition by Abbott Laboratories.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EXAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EXAS
Wall Street analysts forecast EXAS stock price to fall
20 Analyst Rating
1 Buy
19 Hold
0 Sell
Hold
Current: 103.430
Low
78.00
Averages
100.20
High
105.00
Current: 103.430
Low
78.00
Averages
100.20
High
105.00
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Laboratories: A Steady Dividend Growth King
- Diversified Business Structure: Abbott Laboratories operates across four business units—diagnostics, medical devices, nutrition, and established pharmaceuticals—ensuring that if one segment faces challenges, others can compensate, thereby enhancing overall financial stability.
- Medical Device Growth: Despite a decline in coronavirus testing sales impacting the diagnostics segment, the medical devices division reported double-digit sales growth in the latest quarter, demonstrating the company's strong performance in innovation and market demand.
- Acquisition-Driven Growth: Abbott is set to complete its acquisition of Exact Sciences, a leader in the cancer screening market, in the second quarter, a strategic move expected to further drive earnings growth and solidify its leadership in the healthcare sector.
- Sustained Dividend Growth: Abbott has increased its dividend for 54 consecutive years, with a 70% increase over the past five years, currently paying $2.52 per share with a yield of 2.2%, showcasing the company's robust cash flow and commitment to shareholder returns.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating companies like Coterra Energy Inc. and Exact Sciences Corporation for potential violations of federal securities laws and fiduciary duties to shareholders, aiming to protect investor rights and seek compensation.
- Coterra Energy Transaction: Coterra Energy Inc. is in a transaction with Devon Energy Corporation, offering shareholders 0.70 shares of Devon common stock for each share of Coterra, with Halper Sadeh LLC potentially seeking to increase the transaction consideration to safeguard shareholder interests.
- Exact Sciences Acquisition: Exact Sciences Corporation is being sold to Abbott for $105.00 per share in cash, and Halper Sadeh LLC encourages Exact shareholders to reach out to understand their legal rights, potentially seeking additional disclosures and compensation.
- Merger Investigation: The merger between Northfield Bancorp, Inc. and Columbia Financial, Inc. is also under investigation, with Halper Sadeh LLC representing shareholders to seek increased transaction consideration and other relief measures to ensure the protection of shareholder rights.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Shareholder Voting Schedule: Exact Sciences Corporation is set to hold a shareholder vote on February 20, 2026, where shareholders are expected to receive $105.00 per share, indicating a strong market expectation for the transaction's success and potential financial benefits for investors.
- Equity Distribution Post-Merger: Following the merger with CNL Healthcare Properties, Inc., Sonida Senior Living, Inc. shareholders will own between 39.5% and 50.0% of the new company, which will significantly influence governance and strategic decisions moving forward.
- Impact of FirstSun Merger: The merger between FirstSun Capital Bancorp and First Foundation Inc. will result in FirstSun shareholders owning 59.5% of the combined entity, reflecting a positive outlook for shareholder interests and potentially boosting market confidence in the merged company.
- Prospects for Tamboran Merger: Tamboran Resources Corporation's merger with Falcon Oil & Gas Ltd. will allow Tamboran shareholders to hold 73.2% of the new company, providing substantial control and potential financial gains for shareholders, which may enhance their investment outlook.
See More
3 Strategies to Calm Stock Market Anxiety Ahead of Key Jobs Report
Stock Market Outlook: The Super Bowl Indicator suggests a positive year for the stock market, particularly following the Seattle Seahawks' victory.
Investor Sentiment: Even skeptics of the Super Bowl Indicator can find reasons for optimism as the market approaches a significant January jobs report.
See More
Hims & Hers Introduces New Cancer Test, But It Might Not Be Fully Prepared for Use.
Super Bowl Ad Controversy: Hims & Hers has released a new Super Bowl ad that is raising concerns among medical experts.
Promotion of Medical Products: The ad promotes the company's weight loss drugs, testosterone treatments, and a controversial early cancer detection test.
See More
Exact Sciences' Sale to Abbott Clears HSR Waiting Period
- Transaction Progress: Exact Sciences (EXAS) shares rose 0.5% as reports confirmed that the HSR waiting period for its $21 billion all-cash acquisition by Abbott Laboratories (ABT) expired on Thursday, indicating the deal has cleared antitrust scrutiny and boosting market confidence in its success.
- Market Reaction: Following the news, Abbott (ABT) shares also increased by 0.5%, reflecting investor optimism regarding the acquisition, which is expected to enhance Abbott's market share and growth in the cancer screening sector.
- Deal Background: Abbott announced the acquisition of Exact Sciences last November, valuing the deal at $105 per share, aimed at strengthening its competitive position in the cancer screening market, aligning with its long-term growth strategy.
- Investor Interest: Although Exact Sciences and Abbott did not immediately respond to media inquiries, the positive sentiment surrounding the deal may attract more investor attention, particularly regarding technological innovations and market potential in the cancer screening field.
See More
Abbott Laboratories: A Steady Dividend Growth King
- Diversified Business Structure: Abbott Laboratories operates across four business units—diagnostics, medical devices, nutrition, and established pharmaceuticals—ensuring that if one segment faces challenges, others can compensate, thereby enhancing overall financial stability.
- Medical Device Growth: Despite a decline in coronavirus testing sales impacting the diagnostics segment, the medical devices division reported double-digit sales growth in the latest quarter, demonstrating the company's strong performance in innovation and market demand.
- Acquisition-Driven Growth: Abbott is set to complete its acquisition of Exact Sciences, a leader in the cancer screening market, in the second quarter, a strategic move expected to further drive earnings growth and solidify its leadership in the healthcare sector.
- Sustained Dividend Growth: Abbott has increased its dividend for 54 consecutive years, with a 70% increase over the past five years, currently paying $2.52 per share with a yield of 2.2%, showcasing the company's robust cash flow and commitment to shareholder returns.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating companies like Coterra Energy Inc. and Exact Sciences Corporation for potential violations of federal securities laws and fiduciary duties to shareholders, aiming to protect investor rights and seek compensation.
- Coterra Energy Transaction: Coterra Energy Inc. is in a transaction with Devon Energy Corporation, offering shareholders 0.70 shares of Devon common stock for each share of Coterra, with Halper Sadeh LLC potentially seeking to increase the transaction consideration to safeguard shareholder interests.
- Exact Sciences Acquisition: Exact Sciences Corporation is being sold to Abbott for $105.00 per share in cash, and Halper Sadeh LLC encourages Exact shareholders to reach out to understand their legal rights, potentially seeking additional disclosures and compensation.
- Merger Investigation: The merger between Northfield Bancorp, Inc. and Columbia Financial, Inc. is also under investigation, with Halper Sadeh LLC representing shareholders to seek increased transaction consideration and other relief measures to ensure the protection of shareholder rights.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Shareholder Voting Schedule: Exact Sciences Corporation is set to hold a shareholder vote on February 20, 2026, where shareholders are expected to receive $105.00 per share, indicating a strong market expectation for the transaction's success and potential financial benefits for investors.
- Equity Distribution Post-Merger: Following the merger with CNL Healthcare Properties, Inc., Sonida Senior Living, Inc. shareholders will own between 39.5% and 50.0% of the new company, which will significantly influence governance and strategic decisions moving forward.
- Impact of FirstSun Merger: The merger between FirstSun Capital Bancorp and First Foundation Inc. will result in FirstSun shareholders owning 59.5% of the combined entity, reflecting a positive outlook for shareholder interests and potentially boosting market confidence in the merged company.
- Prospects for Tamboran Merger: Tamboran Resources Corporation's merger with Falcon Oil & Gas Ltd. will allow Tamboran shareholders to hold 73.2% of the new company, providing substantial control and potential financial gains for shareholders, which may enhance their investment outlook.
See More
3 Strategies to Calm Stock Market Anxiety Ahead of Key Jobs Report
Stock Market Outlook: The Super Bowl Indicator suggests a positive year for the stock market, particularly following the Seattle Seahawks' victory.
Investor Sentiment: Even skeptics of the Super Bowl Indicator can find reasons for optimism as the market approaches a significant January jobs report.
See More
Hims & Hers Introduces New Cancer Test, But It Might Not Be Fully Prepared for Use.
Super Bowl Ad Controversy: Hims & Hers has released a new Super Bowl ad that is raising concerns among medical experts.
Promotion of Medical Products: The ad promotes the company's weight loss drugs, testosterone treatments, and a controversial early cancer detection test.
See More
Exact Sciences' Sale to Abbott Clears HSR Waiting Period
- Transaction Progress: Exact Sciences (EXAS) shares rose 0.5% as reports confirmed that the HSR waiting period for its $21 billion all-cash acquisition by Abbott Laboratories (ABT) expired on Thursday, indicating the deal has cleared antitrust scrutiny and boosting market confidence in its success.
- Market Reaction: Following the news, Abbott (ABT) shares also increased by 0.5%, reflecting investor optimism regarding the acquisition, which is expected to enhance Abbott's market share and growth in the cancer screening sector.
- Deal Background: Abbott announced the acquisition of Exact Sciences last November, valuing the deal at $105 per share, aimed at strengthening its competitive position in the cancer screening market, aligning with its long-term growth strategy.
- Investor Interest: Although Exact Sciences and Abbott did not immediately respond to media inquiries, the positive sentiment surrounding the deal may attract more investor attention, particularly regarding technological innovations and market potential in the cancer screening field.
See More
